Jackie is an industry expert with two decades of legal and strategic leadership experience, with proven skills in navigating a wide array of legal and compliance issues through clinical development and commercialization of novel therapies. Prior to joining Cullinan Therapeutics, Jackie was Chief Legal and Compliance Officer at Genocea Biosciences, Inc., where she led all legal, intellectual property, and compliance strategy and operations. Previously, Jackie was Vice President, Assistant General Counsel at Bristol Myers Squibb, where she led the Worldwide Hematology and Cell Therapy legal team, and prior to that, she was head of Celgene Corporation’s CAR T legal team.
In both roles she supported the development and commercialization of multiple hematology medicines. Earlier in her career, Jackie held positions of increasing responsibility at Novartis Global Oncology and Novartis Pharmaceuticals Corporation, where she provided counsel on a range of matters relating to preclinical and clinical development, commercialization, employment, litigation and government investigations, and compliance.
Jackie began her legal career at Kaye Scholer, LLP, and clerked for the Honorable Gladys Kessler of the United States District Court in Washington, DC. She holds a JD and a LLM in international and comparative law from Duke University School of Law and a BA from Bucknell University.
What is Jacquelyn L. Sumer's net worth?
The estimated net worth of Jacquelyn L. Sumer is at least $1.91 million as of February 24th, 2026. Sumer owns 128,089 shares of Cullinan Therapeutics stock worth more than $1,909,807 as of March 11th. This net worth approximation does not reflect any other investments that Sumer may own. Learn More about Jacquelyn L. Sumer's net worth.
How old is Jacquelyn L. Sumer?
Sumer is currently 46 years old. There are 6 older executives and no younger executives at Cullinan Therapeutics. The oldest executive at Cullinan Therapeutics is Dr. Patrick A. Baeuerle Ph.D., Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board, who is 66 years old. Learn More on Jacquelyn L. Sumer's age.
How do I contact Jacquelyn L. Sumer?
Has Jacquelyn L. Sumer been buying or selling shares of Cullinan Therapeutics?
In the last ninety days, Jacquelyn L. Sumer has sold $103,072.51 of Cullinan Therapeutics stock. Most recently, Jacquelyn L. Sumer sold 3,601 shares of the business's stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $14.47, for a transaction totalling $52,106.47. Following the completion of the sale, the insider now directly owns 128,089 shares of the company's stock, valued at $1,853,447.83. Learn More on Jacquelyn L. Sumer's trading history.
Who are Cullinan Therapeutics' active insiders?
Are insiders buying or selling shares of Cullinan Therapeutics?
During the last twelve months, Cullinan Therapeutics insiders bought shares 8 times. They purchased a total of 1,874,057 shares worth more than $13,325,286.34. During the last twelve months, insiders at the sold shares 22 times. They sold a total of 111,912 shares worth more than $1,469,441.02. The most recent insider tranaction occured on March, 5th when insider Jennifer Michaelson sold 8,000 shares worth more than $125,440.00. Insiders at Cullinan Therapeutics own 6.1% of the company.
Learn More about insider trades at Cullinan Therapeutics. Information on this page was last updated on 3/5/2026.
